Schering-Plough Corp. plans to expand its business overseas as government pressures and negative news coverage of its studies on cholesterol drug Vytorin pull down U.S. sales, CEO Fred Hassan said. The drugmaker has been entering markets that the industry generally ignores because "half-a-billion people are moving into the middle class," Hassan said.

Full Story:

Related Summaries